SAM
CBPO

Symphony Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Symphony Asset Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,431
Closed -$328K – 516
2015
Q1 		$328K Buy
+3,431
New +$257K 0.04% 405

Other funds holding CBPO

WP
Warburg Pincus New York $343M AUM 18.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
BlackRock Group London, United Kingdom $210B AUM 15.5% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Symphony Asset Management's CBPO Position: Q2 2015 in Review

Symphony Asset Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q2 2015, closing a stake of 3,431 shares — an estimated $328K sold.

Symphony Asset Management first reported a position in CBPO in Q1 2015 and held it in 1 quarter. The position peaked at $328K in Q1 2015. 109 funds tracked by Wall St. Rank hold CBPO as of Q2 2015.

  • Symphony Asset Management reported no remaining China Biologic Products Holdings, Inc. position as of Q2 2015 after selling out during the quarter.
  • Symphony Asset Management sold 3,431 China Biologic Products Holdings, Inc. shares in Q2 2015, an estimated $328K.
  • Symphony Asset Management first reported a position in China Biologic Products Holdings, Inc. in Q1 2015 and held it in 1 quarter.
  • Symphony Asset Management's China Biologic Products Holdings, Inc. position peaked at $328K in Q1 2015.
  • 109 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q2 2015.

Based on Symphony Asset Management's 13F filing for Q2 2015, filed 12 Aug 2015.